Fly News Breaks for April 11, 2019
Apr 11, 2019 | 07:31 EDT
Cantor Fitzgerald analyst Charles Duncan left investor meetings with Aimmune Therapeutics management with "enhanced conviction" about AR101's approvability and commercial prospects. He believes the regulatory review with the FDA is "now gaining traction." The analyst views 2019 and 2020 as being transformational for Aimmune "as it evolves from being development stage to becoming a fully-integrated commercial stage company." Importantly, the company has sufficient cash to fully fund through the approval and early commercialization in the U.S. and Europe, Duncan tells investors in a research note. He reiterates an Overweight rating on the shares with a $45 price target.
News For AIMT From the Last 2 Days
Jun 17, 2019 | 06:25 EDT
Goldman Sachs analyst Graig Suvannavejh started DBV Technologies (DBVT) with a Buy rating and $14 price target. DBVT is a late-stage specialty biotech company, with a proprietary technology platform that could be used to treat a range of food allergies, Suvannavejh tells investors in a research note. The analyst sees 66% upside from current share levels given the potential catalysts over the next 18 months, which include the Biologics License Applications re-filing in Q3 and FDA acceptance in Q4, a potential panel hearing in mid-2020, and likely final U.S. approval by the end of 2020. Suvannavejh sees an 85% probability of success for DBV's Viaskin Peanut and views the treatment as a more compelling option versus Aimmune's (AIMT) AR101 on overall safety and product presentation profiles.